207 related articles for article (PubMed ID: 24121490)
21. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
Yamazaki S
AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
[TBL] [Abstract][Full Text] [Related]
22. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
Lev A; Deihimi S; Shagisultanova E; Xiu J; Lulla AR; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2017 Sep; 18(9):694-704. PubMed ID: 28886275
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
Li YQ; Song SS; Jiang SH; Zhang XY
Ann Oncol; 2017 Oct; 28(10):2622-2624. PubMed ID: 28961830
[No Abstract] [Full Text] [Related]
25. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
[TBL] [Abstract][Full Text] [Related]
27. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
Etnyre D; Stone AL; Fong JT; Jacobs RJ; Uppada SB; Botting GM; Rajanna S; Moravec DN; Shambannagari MR; Crees Z; Girard J; Bertram C; Puri N
Cancer Biol Ther; 2014 Sep; 15(9):1129-41. PubMed ID: 24914950
[TBL] [Abstract][Full Text] [Related]
28. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
[No Abstract] [Full Text] [Related]
29. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
[TBL] [Abstract][Full Text] [Related]
30. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
31. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
Kim B; Wang S; Lee JM; Jeong Y; Ahn T; Son DS; Park HW; Yoo HS; Song YJ; Lee E; Oh YM; Lee SB; Choi J; Murray JC; Zhou Y; Song PH; Kim KA; Weiner LM
Oncogene; 2015 Feb; 34(9):1083-93. PubMed ID: 24662823
[TBL] [Abstract][Full Text] [Related]
32. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
33. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
[TBL] [Abstract][Full Text] [Related]
35. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
Avan A; Caretti V; Funel N; Galvani E; Maftouh M; Honeywell RJ; Lagerweij T; Van Tellingen O; Campani D; Fuchs D; Verheul HM; Schuurhuis GJ; Boggi U; Peters GJ; Würdinger T; Giovannetti E
Cancer Res; 2013 Nov; 73(22):6745-56. PubMed ID: 24085787
[TBL] [Abstract][Full Text] [Related]
36. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
37. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
38. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J
Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
Takiguchi S; Inoue K; Matsusue K; Furukawa M; Teramoto N; Iguchi H
Int J Oncol; 2017 Jul; 51(1):184-192. PubMed ID: 28498406
[TBL] [Abstract][Full Text] [Related]
40. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
